Early drug trial aims to stop blood cancer before it starts

This early-stage study is testing if a drug called ropeginterferon is safe and feasible to use in people who have a specific genetic change (JAK2 mutation) that puts them at high risk for developing blood cancers or blood clots, but who do not yet have the cancer. The main goals are to see if researchers can enroll 12 suitable participants and to check the drug's safety. Participants will receive a monthly injection for up to two years and have regular clinic checkups.